Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Blow-Fill-Seal Sterile CDMO Business is focusing on complex clinical to commercial-stage formulation and manufacturing. The Business supports a global, blue-chip customer base with a broad array of products that leverage its BFS sterile manufacturing capabilities and formulation competency in complex chemistries including small molecule, biologics, macromolecules, and potent compounds.

SOMERSET, N.J.--( BUSINESS WIRE )--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that current board member and lead independent director J. Martin (“Marty”) Carroll has been unanimously selected by its Board of Directors to succeed John Chiminski and serve as Chair following Mr. Chiminski's retirement.

Catalent Announces Changes to its Board of Directors

Catalent's (CTLT) latest capability expansion is expected to boost its business in the clinical trials space in its Asia-Pacific Clinical Supply Services network.

Catalent (CTLT) Expands Facility Capabilities in Shanghai

BeiGene

Bio-Rad Laboratories

DexCom

Edwards Lifesciences

Gilead Sciences

Intuitive Surgical

Moderna

Seagen

West Pharmaceutical Services

The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.

These Are the Five Best and Worst Performing Healthcare Stocks in October 2022

Carrier Global

Caesars Entertainment

Etsy

Match Group

Otis Worldwide

Stanley Black & Decker

Tesla

Zoetis

Tesla isn't the only stock that's struggling in 2022. Nearly 60 S&P 500 stocks — or about 11% — are having their worst year ever.

11% Of S&P 500 Stocks Suffer Their Worst Year Ever

Align Technology

Generac Holdings

PayPal

Signature Bank

SVB Financial Group

V.F.

Warner Bros Discovery Inc

Zebra Technologies

It's been a bad year for most S&P 500 investors. But it's been a disaster for those who owned the biggest turkeys.

Do You Own The Year's 12 Biggest Stock Market Turkeys?

Earnings estimates have slipped for this stock following the most recent earnings miss.

Bear Of The Day: Catalent (CTLT)

With the macro backdrop weakening for Catalent's pharmaceutical and biotech customers, fundamental concerns could outweigh what the charts suggest.

After a $100 Haircut, is Catalent an Oversold Pharma Play?

Catalent, Inc. to Present at the Stephens Annual Investment Conference

Lowered guidance and earnings concerned investors.

Why Shares of Catalent Fell 36% This Week

Exelixis

Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis' Biologics Pipeline

Flat revenue growth, a sharp decline in profitability, and reduced guidance combined to make an awful day for the company.

Why Catalent Stock Plummeted by Nearly 25% Today

Catalent, Inc. (NYSE:CTLT ) Q1 2023 Earnings Conference Call November 1, 2022 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations Alessandro Maselli - President & Chief Executive Officer Tom Castellano - Senior Vice President & Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Sean Dodge - RBC Capital Markets Dave Windley - Jefferies Derik De Bruin - Bank of America Max Smock - William Blair Justin Bowers - Deutsche Bank John Sourbeer - UBS Jack Meehan - Nephron Research Evan Stover - Baird. Luke Sergott - Barclays Operator Hello everyone and welcome to the Catalent Inc. First Quarter Fiscal Year 2023 Earnings Conference Call.

Catalent, Inc. (CTLT) Q1 2023 Earnings Call Transcript

Shares of Catalent Inc. CTLT, -23.31% plunged 23.4% toward a record one-day selloff, and enough to pace the S&P 500's SPX, -0.35% losers, after the contract drug manufacturing company reported fiscal first-quarter profit and revenue that missed expectations and cut its full-year outlook. The stock's previous record one-day drop was 18.7% on March 16, 2020.

Catalent stock paces S&P 500 losers as it suffers record selloff after earnings miss, lowered outlook

Catalent (CTLT) records robust first-quarter fiscal 2023 results of its Pharma and Consumer Health segment despite overall soft performance.

Catalent (CTLT) Q1 Earnings Lag Estimates, FY23 View Cut

Catalent (NYSE: CTLT ) stock is falling hard on Tuesday as investors react to dismal results in its earnings report for the fiscal first quarter of 2023. The bad news for investors in CTLT stock starts with its adjusted earnings per share of 34 cents.

Why Is Catalent (CTLT) Stock Down 24% Today?

Catalent (CTLT) delivered earnings and revenue surprises of -38.18% and 4.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Q1 Earnings and Revenues Miss Estimates

Catalent, Inc. Reports First Quarter Fiscal 2023 Results

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Catalent (CTLT) to Report a Decline in Earnings: What to Look Out for

Catalent, Inc. Announces First Quarter Fiscal Year 2023 Earnings Conference Webcast

Biogen

Constellation Energy Corp

Charter Communications

Enphase Energy

FedEx

Lumen Technologies

Netflix

Cramer said he wouldn't touch this stock with a 10 foot pole.

Jim Cramer goes over the best and worst Q3 performers in the S&P 500

Jazz Pharmaceuticals

JAZZ vs. CTLT: Which Stock Is the Better Value Option?

The market has had a terrible run. Barron's takes a look at the winners and losers this quarter.

The 5 Best—and 5 Worst—S&P 500 Stocks in the Third Quarter

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?

Why Is Catalent (CTLT) Down 18.5% Since Last Earnings Report?

Amazon

Alexandria Real Estate Equities

Bath and Body Works

Salesforce

Alphabet

IQVIA Hlds

Labcorp Holdings Inc

Microsoft

ServiceNow

Teradyne

Wall Street analysts follow S&P 500 stocks more closely than almost anyone. But even they get it wrong sometimes, too.

Analysts Totally Blow It On 12 Gutsy Stock Recommendations

Ball Corp

Cardinal Health

DXC Technology

EPAM Systems

Nielsen Hlds

SolarEdge Technologies

EPAM Systems was the best performer in the index in August. Ball Corp. was the worst.

The 5 Best and 5 Worst Performers in the S&P 500 in August

News for Catalent Stock (CTLT)